Novo Giuseppina, Guarino Tommaso, Di Lisi Daniela, Biagioli Paolo, Carluccio Erberto
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialities, University of Palermo, Cardiology Unit, University Hospital P. Giaccone, Palermo, Italy.
Cardiology and Cardiovascular Pathophysiology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Heart Fail Rev. 2023 May;28(3):697-707. doi: 10.1007/s10741-022-10256-4. Epub 2022 Jun 16.
SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the presence or absence of diabetes in patients at high cardiovascular risk and in those with heart failure and reduced ejection fraction (HFrEF). In patients with HF and preserved EF, empagliflozin also showed favorable effects mainly related to the reduction of hospitalization for heart failure. These favorable effects are beyond the reduction of glycemic levels and mainly related to beneficial hemodynamic and anti-inflammatory effects of these drugs and improved cardiac energy metabolism. In this review, we aimed to evaluate the effects of SGLT2 inhibitor on cardiac remodeling and function, which is still incompletely clear.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂可降低心血管死亡风险或因心力衰竭住院的风险，无论心血管风险高的患者有无糖尿病，以及射血分数降低的心力衰竭（HFrEF）患者情况如何。在射血分数保留的心力衰竭（HFpEF）患者中，恩格列净也显示出主要与降低因心力衰竭住院风险相关的有益作用。这些有益作用不仅限于血糖水平的降低，主要与这些药物有益的血流动力学和抗炎作用以及改善心肌能量代谢有关。在本综述中，我们旨在评估SGLT2抑制剂对心脏重塑和功能的影响，目前这方面仍不完全清楚。
